Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | JAK1 | P23458 | 1/20 | 0.54 |
| ▸ | TYK2 | P29597 | 1/20 | 0.54 |
| ▸ | JAK3 | P52333 | 1/20 | 0.54 |
| ▸ | QPCT | Q16769 | 1/20 | 0.51 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14415981 | 0.92 | HRH3 (0.64) | HRH3HRH4EPHX1 | |
| SCHEMBL4681311 | 0.83 | CXCR4 (0.57) | HRH3HRH4 | |
| SCHEMBL22701433 | 0.77 | HRH3 (0.80) | HRH3HRH4 | |
| SCHEMBL13073926 | 0.75 | HRH3 (0.77) | HRH3HRH4MEN1ALDH1A1MAPT | |
| SCHEMBL3934417 | 0.75 | HRH3 (0.61) | HRH3HRH4MEN1ALDH1A1MAPT | |
| SCHEMBL26399751 | 0.74 | EPHX1 (0.61) | HRH3HRH4QPCTQPCTLEPHX1 | |
| SCHEMBL26399531 | 0.74 | EPHX1 (0.61) | HRH3HRH4QPCTQPCTLEPHX1 | |
| SCHEMBL289187 | 0.73 | QPCT (0.59) | HRH3HRH4MEN1ALDH1A1MAPT | |
| SCHEMBL21859233 | 0.73 | QPCT (0.63) | HRH3HRH4MEN1ALDH1A1MAPT | |
| SCHEMBL14415979 | 0.71 | HRH4 (0.79) | HRH3HRH4MEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1416933-B8 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2007-09-13 | — | — | US | disclosed |
| EP-1416933-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | Amgem, Inc. (US) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003009847-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEM, INC. (US) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | FNTB, FNTA, FDPS | HRH3 3867/4885HRH4 2441/4885MEN1 2209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.